Coverage
-
January 26, 2018
The U.S. Supreme Court on Thursday shot down Helsinn Healthcare's bid to hit pause on a Federal Circuit decision invalidating four Helsinn patents related to an anti-nausea drug under the America Invents Act's on-sale bar, refusing to hold up the ruling while the pharmaceutical company pursues a high court review of the case.
10 other articles on this case.
View all »